# US 2023/0399639 A1 · Compositions comprising an rna guide targeting b2m and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399639 A1
- Document ID: US20230399639A1
- Status: Published application
- Kind: A1
- Application number: 18/034,609
- Filed: 2021-10-29
- Published: 2023-12-14
- Earliest claimed: 2020-10-30
- Assignees: Arbor Biotechnologies, Inc.
- Applicants: Arbor Biotechnologies, Inc.
- Inventors: Quinton Norman Wessells; Jeffrey Raymond Haswell; Tia Marie DiTommaso; Noah Michael Jakimo
- Web page: https://patentgrep.com/patent/US20230399639A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/1138: {against receptors or cell surface proteins}
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/907: {in mammalian cells}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to compositions comprising RNA guides targeting B2M, processes for characterizing the compositions, cells comprising the compositions, and methods of using the compositions.

## Claims

### Claim 1

A composition comprising an RNA guide, wherein the RNA guide comprises (i) a spacer sequence that is substantially complementary to a target sequence within a B2M gene and (ii) a direct repeat sequence; wherein the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the sequence 5′-NTTN-3′.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the target sequence is within exon 1, exon 2, exon 3, exon 4, intron 1, intron 2, or intron 3 of the B2M gene.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or 2, wherein the B2M gene comprises the sequence of SEQ ID NO: 773, the reverse complement of SEQ ID NO: 773, a variant of SEQ ID NO: 773, or the reverse complement of a variant of SEQ ID NO: 773.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1 to 3, wherein the spacer sequence comprises:
a. nucleotide 1 through nucleotide 16 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
b. nucleotide 1 through nucleotide 17 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
c. nucleotide 1 through nucleotide 18 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
d. nucleotide 1 through nucleotide 19 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
e. nucleotide 1 through nucleotide 20 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
f. nucleotide 1 through nucleotide 21 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770;
g. nucleotide 1 through nucleotide 22 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 554-770;
h. nucleotide 1 through nucleotide 23 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 555-770;
i. nucleotide 1 through nucleotide 24 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
j. nucleotide 1 through nucleotide 25 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
k. nucleotide 1 through nucleotide 26 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
l. nucleotide 1 through nucleotide 27 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
m. nucleotide 1 through nucleotide 28 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
n. nucleotide 1 through nucleotide 29 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770; or
o. nucleotide 1 through nucleotide 30 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-540, 542-552, and 556-770.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1 to 4, wherein the spacer sequence comprises:
a. nucleotide 1 through nucleotide 16 of any one of SEQ ID NOs: 391-770 or 1019-1218;
b. nucleotide 1 through nucleotide 17 of any one of SEQ ID NOs: 391-770 or 1019-1218;
c. nucleotide 1 through nucleotide 18 of any one of SEQ ID NOs: 391-770 or 1019-1218;
d. nucleotide 1 through nucleotide 19 of any one of SEQ ID NOs: 391-770 or 1019-1218;
e. nucleotide 1 through nucleotide 20 of any one of SEQ ID NOs: 391-770 or 1019-1218;
f. nucleotide 1 through nucleotide 21 of any one of SEQ ID NOs: 391-770;
g. nucleotide 1 through nucleotide 22 of any one of SEQ ID NOs: 391-552 and 554-770;
h. nucleotide 1 through nucleotide 23 of any one of SEQ ID NOs: 391-552 and 555-770;
i. nucleotide 1 through nucleotide 24 of any one of SEQ ID NOs: 391-552 and 556-770;
j. nucleotide 1 through nucleotide 25 of any one of SEQ ID NOs: 391-552 and 556-770;
k. nucleotide 1 through nucleotide 26 of any one of SEQ ID NOs: 391-552 and 556-770;
l. nucleotide 1 through nucleotide 27 of any one of SEQ ID NOs: 391-552 and 556-770;
m. nucleotide 1 through nucleotide 28 of any one of SEQ ID NOs: 391-552 and 556-770;
n. nucleotide 1 through nucleotide 29 of any one of SEQ ID NOs: 391-552 and 556-770; or
o. nucleotide 1 through nucleotide 30 of any one of SEQ ID NOs: 391-540, 542-552, and 556-770.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
o. nucleotide 1 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
p. nucleotide 2 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
q. nucleotide 3 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
r. nucleotide 4 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
s. nucleotide 5 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO:9;
t. nucleotide 6 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
u. nucleotide 7 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
v. nucleotide 8 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
w. nucleotide 9 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
x. nucleotide 10 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
y. nucleotide 11 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
z. nucleotide 12 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9; or
aa. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 10 or a portion thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
b. nucleotide 2 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
c. nucleotide 3 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
d. nucleotide 4 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
e. nucleotide 5 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
f. nucleotide 6 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
g. nucleotide 7 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
h. nucleotide 8 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
i. nucleotide 9 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
j. nucleotide 10 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
k. nucleotide 11 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
l. nucleotide 12 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
m. nucleotide 13 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
n. nucleotide 14 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
o. nucleotide 1 through nucleotide 34 of SEQ ID NO: 9;
p. nucleotide 2 through nucleotide 34 of SEQ ID NO: 9;
q. nucleotide 3 through nucleotide 34 of SEQ ID NO: 9;
r. nucleotide 4 through nucleotide 34 of SEQ ID NO: 9;
s. nucleotide 5 through nucleotide 34 of SEQ ID NO: 9;
t. nucleotide 6 through nucleotide 34 of SEQ ID NO: 9;
u. nucleotide 7 through nucleotide 34 of SEQ ID NO: 9;
v. nucleotide 8 through nucleotide 34 of SEQ ID NO: 9;
w. nucleotide 9 through nucleotide 34 of SEQ ID NO: 9;
x. nucleotide 10 through nucleotide 34 of SEQ ID NO: 9;
y. nucleotide 11 through nucleotide 34 of SEQ ID NO: 9;
z. nucleotide 12 through nucleotide 34 of SEQ ID NO: 9; or
aa. SEQ ID NO: 10 or a portion thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805; or
o. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 806 or a portion thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 8)

The composition of any one of claims 1 to 5 or 8, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
b. nucleotide 2 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
c. nucleotide 3 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
d. nucleotide 4 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
e. nucleotide 5 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
f. nucleotide 6 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
g. nucleotide 7 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
h. nucleotide 8 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
i. nucleotide 9 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
j. nucleotide 10 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
k. nucleotide 11 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
l. nucleotide 12 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
m. nucleotide 13 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
n. nucleotide 14 through nucleotide 36 of any one of SEQ ID NOs: 788-805; or
o. SEQ ID NO: 806 or a portion thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807; or
o. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 808 or SEQ ID NO: 809 or a portion thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 10)

The composition of any one of claims 1 to 5 or 10, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of SEQ ID NO: 807;
b. nucleotide 2 through nucleotide 36 of SEQ ID NO: 807;
c. nucleotide 3 through nucleotide 36 of SEQ ID NO: 807;
d. nucleotide 4 through nucleotide 36 of SEQ ID NO: 807;
e. nucleotide 5 through nucleotide 36 of SEQ ID NO: 807;
f. nucleotide 6 through nucleotide 36 of SEQ ID NO: 807;
g. nucleotide 7 through nucleotide 36 of SEQ ID NO: 807;
h. nucleotide 8 through nucleotide 36 of SEQ ID NO: 807;
i. nucleotide 9 through nucleotide 36 of SEQ ID NO: 807;
j. nucleotide 10 through nucleotide 36 of SEQ ID NO: 807;
k. nucleotide 11 through nucleotide 36 of SEQ ID NO: 807;
l. nucleotide 12 through nucleotide 36 of SEQ ID NO: 807;
m. nucleotide 13 through nucleotide 36 of SEQ ID NO: 807;
n. nucleotide 14 through nucleotide 36 of SEQ ID NO: 807; or
o. SEQ ID NO: 808 or SEQ ID NO: 809 or a portion thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
o. nucleotide 15 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811; or
p. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 812 or a portion thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 12)

The composition of any one of claims 1 to 5 or 12, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
b. nucleotide 2 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
c. nucleotide 3 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
d. nucleotide 4 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
e. nucleotide 5 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
f. nucleotide 6 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
g. nucleotide 7 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
h. nucleotide 8 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
i. nucleotide 9 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
j. nucleotide 10 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
k. nucleotide 11 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
l. nucleotide 12 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
m. nucleotide 13 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
n. nucleotide 14 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
o. nucleotide 15 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811; or
p. SEQ ID NO: 812 or a portion thereof.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the spacer sequence is substantially complementary to the complement of a sequence of any one of SEQ ID NOs: 11-390 or 819-1018.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the PAM comprises the sequence 5′-ATTA-3′, 5′-ATTT-3′, 5′-ATTG-3′, 5′-ATTC-3′, 5′-TTTA-3′, 5′-TTTT-3′, 5′-TTTG-3′, 5′-TTTC-3′, 5′-GTTA-3′, 5′-GTTT-3′, 5′-GTTG-3′, 5′-GTTC-3′, 5′-CTTA-3′, 5′-CTTT-3′, 5′-CTTG-3′, or 5′-CTTC-3′.

### Claim 16 (depends on 1, 15)

The composition of claim 1 or 15, wherein the target sequence is immediately adjacent to the PAM sequence.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 1 to 16, wherein the composition further comprises a Cas12i polypeptide.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the Cas12i polypeptide is:
a. a Cas12i2 polypeptide comprising a sequence that is at least 90% identical to the sequence of SEQ ID NO: 772, SEQ ID NO: 782, SEQ ID NO: 783, SEQ ID NO: 784, SEQ ID NO: 785, or SEQ ID NO: 786;
b. a Cas12i4 polypeptide comprising a sequence that is at least 90% identical to the sequence of SEQ ID NO: 814, SEQ ID NO: 815, or SEQ ID NO: 816;
c. a Cas12i1 polypeptide comprising a sequence that is at least 90% identical to the sequence of SEQ ID NO: 817; or
d. a Cas12i3 polypeptide comprising a sequence that is at least 90% identical to the sequence of SEQ ID NO: 818.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the Cas12i polypeptide is:
a. a Cas12i2 polypeptide comprising a sequence of SEQ ID NO: 772, SEQ ID NO: 782, SEQ ID NO: 783, SEQ ID NO: 784, SEQ ID NO: 785, or SEQ ID NO: 786;
b. a Cas12i4 polypeptide comprising a sequence of SEQ ID NO: 814, SEQ ID NO: 815, or SEQ ID NO: 816;
c. a Cas12i1 polypeptide comprising a sequence of SEQ ID NO: 817; or
d. a Cas12i3 polypeptide comprising a sequence of SEQ ID NO: 818.

### Claim 20 (depends on 17, 18, 19)

The composition of any one of claims 17 to 19, wherein the RNA guide and the Cas12i polypeptide form a ribonucleoprotein complex.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the ribonucleoprotein complex binds a target nucleic acid.

### Claim 22 (depends on 20, 21)

The composition of claim 20 or 21, wherein the composition is present within a cell.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The composition of any one of claims 17 to 22, wherein the RNA guide and the Cas12i polypeptide are encoded in a vector, e.g., expression vector.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the RNA guide and the Cas12i polypeptide are encoded in a single vector or the RNA guide is encoded in a first vector and the Cas12i polypeptide is encoded in a second vector.

### Claim 25

An RNA guide comprising (i) a spacer sequence that is substantially complementary to a target sequence within a B2M gene and (ii) a direct repeat sequence.

### Claim 26 (depends on 25)

The RNA guide of claim 25, wherein the target sequence is within exon 1, exon 2, exon 3, exon 4, intron 1, intron 2, or intron 3 of the B2M gene.

### Claim 27 (depends on 25, 26)

The RNA guide of claim 25 or 26, wherein the B2M gene comprises the sequence of SEQ ID NO: 773, the reverse complement of SEQ ID NO: 773, a variant of SEQ ID NO: 773, or the reverse complement of a variant of SEQ ID NO: 773.

### Claim 28 (depends on 25, 26, 27)

The RNA guide of any one of claims 25 to 27, wherein the spacer sequence comprises:
a. nucleotide 1 through nucleotide 16 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
b. nucleotide 1 through nucleotide 17 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
c. nucleotide 1 through nucleotide 18 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
d. nucleotide 1 through nucleotide 19 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
e. nucleotide 1 through nucleotide 20 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770 or 1019-1218;
f. nucleotide 1 through nucleotide 21 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-770;
g. nucleotide 1 through nucleotide 22 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 554-770;
h. nucleotide 1 through nucleotide 23 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 555-770;
i. nucleotide 1 through nucleotide 24 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
j. nucleotide 1 through nucleotide 25 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
k. nucleotide 1 through nucleotide 26 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
l. nucleotide 1 through nucleotide 27 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
m. nucleotide 1 through nucleotide 28 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770;
n. nucleotide 1 through nucleotide 29 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-552 and 556-770; or
o. nucleotide 1 through nucleotide 30 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 391-540, 542-552, and 556-770.

### Claim 29 (depends on 25, 26, 27, 28)

The RNA guide of any one of claims 25 to 28, wherein the spacer sequence comprises:
a. nucleotide 1 through nucleotide 16 of any one of SEQ ID NOs: 391-770 or 1019-1218;
b. nucleotide 1 through nucleotide 17 of any one of SEQ ID NOs: 391-770 or 1019-1218;
c. nucleotide 1 through nucleotide 18 of any one of SEQ ID NOs: 391-770 or 1019-1218;
d. nucleotide 1 through nucleotide 19 of any one of SEQ ID NOs: 391-770 or 1019-1218;
e. nucleotide 1 through nucleotide 20 of any one of SEQ ID NOs: 391-770 or 1019-1218;
f. nucleotide 1 through nucleotide 21 of any one of SEQ ID NOs: 391-770;
g. nucleotide 1 through nucleotide 22 of any one of SEQ ID NOs: 391-552 and 554-770;
h. nucleotide 1 through nucleotide 23 of any one of SEQ ID NOs: 391-552 and 555-770;
i. nucleotide 1 through nucleotide 24 of any one of SEQ ID NOs: 391-552 and 556-770;
j. nucleotide 1 through nucleotide 25 of any one of SEQ ID NOs: 391-552 and 556-770;
k. nucleotide 1 through nucleotide 26 of any one of SEQ ID NOs: 391-552 and 556-770;
l. nucleotide 1 through nucleotide 27 of any one of SEQ ID NOs: 391-552 and 556-770;
m. nucleotide 1 through nucleotide 28 of any one of SEQ ID NOs: 391-552 and 556-770;
n. nucleotide 1 through nucleotide 29 of any one of SEQ ID NOs: 391-552 and 556-770; or
o. nucleotide 1 through nucleotide 30 of any one of SEQ ID NOs: 391-540, 542-552, and 556-770.

### Claim 30 (depends on 25, 26, 27, 28, 29)

The RNA guide of any one of claims 25 to 29, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-8;
o. nucleotide 1 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
p. nucleotide 2 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
q. nucleotide 3 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
r. nucleotide 4 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
s. nucleotide 5 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
t. nucleotide 6 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
u. nucleotide 7 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO:9;
v. nucleotide 8 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
w. nucleotide 9 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
x. nucleotide 10 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
y. nucleotide 11 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9;
z. nucleotide 12 through nucleotide 34 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 9; or
aa. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 10 or a portion thereof.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The RNA guide of any one of claims 25 to 30, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
b. nucleotide 2 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
c. nucleotide 3 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
d. nucleotide 4 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
e. nucleotide 5 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
f. nucleotide 6 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
g. nucleotide 7 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
h. nucleotide 8 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
i. nucleotide 9 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
j. nucleotide 10 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
k. nucleotide 11 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
l. nucleotide 12 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
m. nucleotide 13 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
n. nucleotide 14 through nucleotide 36 of any one of SEQ ID NOs: 1-8;
o. nucleotide 1 through nucleotide 34 of SEQ ID NO: 9;
p. nucleotide 2 through nucleotide 34 of SEQ ID NO: 9;
q. nucleotide 3 through nucleotide 34 of SEQ ID NO: 9;
r. nucleotide 4 through nucleotide 34 of SEQ ID NO: 9;
s. nucleotide 5 through nucleotide 34 of SEQ ID NO: 9;
t. nucleotide 6 through nucleotide 34 of SEQ ID NO: 9;
u. nucleotide 7 through nucleotide 34 of SEQ ID NO: 9;
v. nucleotide 8 through nucleotide 34 of SEQ ID NO: 9;
w. nucleotide 9 through nucleotide 34 of SEQ ID NO: 9;
x. nucleotide 10 through nucleotide 34 of SEQ ID NO: 9;
y. nucleotide 11 through nucleotide 34 of SEQ ID NO: 9;
z. nucleotide 12 through nucleotide 34 of SEQ ID NO: 9; or
aa. SEQ ID NO: 10 or a portion thereof.

### Claim 32 (depends on 25, 26, 27, 28, 29)

The RNA guide of any one of claims 25 to 29, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 788-805; or
o. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 806 or a portion thereof.

### Claim 33 (depends on 25, 26, 27, 28, 29, 32)

The RNA guide of any one of claims 25 to 29 or 32, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
b. nucleotide 2 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
c. nucleotide 3 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
d. nucleotide 4 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
e. nucleotide 5 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
f. nucleotide 6 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
g. nucleotide 7 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
h. nucleotide 8 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
i. nucleotide 9 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
j. nucleotide 10 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
k. nucleotide 11 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
l. nucleotide 12 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
m. nucleotide 13 through nucleotide 36 of any one of SEQ ID NOs: 788-805;
n. nucleotide 14 through nucleotide 36 of any one of SEQ ID NOs: 788-805; or
o. SEQ ID NO: 806 or a portion thereof.

### Claim 34 (depends on 25, 26, 27, 28, 29)

The RNA guide of any one of claims 25 to 29, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to SEQ ID NO: 807; or
o. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 808 or SEQ ID NO: 809 or a portion thereof.

### Claim 35 (depends on 25, 26, 27, 28, 29, 34)

The RNA guide of any one of claims 25 to 29 or 34, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of SEQ ID NO: 807;
b. nucleotide 2 through nucleotide 36 of SEQ ID NO: 807;
c. nucleotide 3 through nucleotide 36 of SEQ ID NO: 807;
d. nucleotide 4 through nucleotide 36 of SEQ ID NO: 807;
e. nucleotide 5 through nucleotide 36 of SEQ ID NO: 807;
f. nucleotide 6 through nucleotide 36 of SEQ ID NO: 807;
g. nucleotide 7 through nucleotide 36 of SEQ ID NO: 807;
h. nucleotide 8 through nucleotide 36 of SEQ ID NO: 807;
i. nucleotide 9 through nucleotide 36 of SEQ ID NO: 807;
j. nucleotide 10 through nucleotide 36 of SEQ ID NO: 807;
k. nucleotide 11 through nucleotide 36 of SEQ ID NO: 807;
l. nucleotide 12 through nucleotide 36 of SEQ ID NO: 807;
m. nucleotide 13 through nucleotide 36 of SEQ ID NO: 807;
n. nucleotide 14 through nucleotide 36 of SEQ ID NO: 807; or
o. SEQ ID NO: 808 or SEQ ID NO: 809 or a portion thereof.

### Claim 36 (depends on 25, 26, 27, 28, 29)

The RNA guide of any one of claims 25 to 29, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
b. nucleotide 2 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
c. nucleotide 3 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
d. nucleotide 4 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
e. nucleotide 5 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
f. nucleotide 6 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
g. nucleotide 7 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
h. nucleotide 8 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
i. nucleotide 9 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
j. nucleotide 10 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
k. nucleotide 11 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
l. nucleotide 12 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
m. nucleotide 13 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
n. nucleotide 14 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811;
o. nucleotide 15 through nucleotide 36 of a sequence that is at least 90% identical to a sequence of SEQ ID NO: 810 or SEQ ID NO: 811; or
p. a sequence that is at least 90% identical to a sequence of SEQ ID NO: 812 or a portion thereof.

### Claim 37 (depends on 25, 26, 27, 28, 29, 36)

The RNA guide of any one of claims 25 to 29 or 36, wherein the direct repeat comprises:
a. nucleotide 1 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
b. nucleotide 2 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
c. nucleotide 3 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
d. nucleotide 4 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
e. nucleotide 5 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
f. nucleotide 6 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
g. nucleotide 7 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
h. nucleotide 8 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
i. nucleotide 9 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
j. nucleotide 10 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
k. nucleotide 11 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
l. nucleotide 12 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
m. nucleotide 13 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
n. nucleotide 14 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811;
o. nucleotide 15 through nucleotide 36 of SEQ ID NO: 810 or SEQ ID NO: 811; or
p. SEQ ID NO: 812 or a portion thereof.

### Claim 38 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The RNA guide of any one of claims 25 to 37, wherein the spacer sequence is substantially complementary to the complement of a sequence of any one of SEQ ID NOs: 11-390 or 819-1018.

### Claim 39 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The RNA guide of any one of claims 25 to 38, wherein the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the sequence 5′-NTTN-3′, wherein N is any nucleotide.

### Claim 40 (depends on 39)

The RNA guide of claim 39, wherein the PAM comprises the sequence 5′-ATTA-3′, 5′-ATTT-3′, 5′-ATTG-3′, 5′-ATTC-3′, 5′-TTTA-3′, 5′-TTTT-3′, 5′-TTTG-3′, 5′-TTTC-3′, 5′-GTTA-3′, 5′-GTTT-3′, 5′-GTTG-3′, 5′-GTTC-3′, 5′-CTTA-3′, 5′-CTTT-3′, 5′-CTTG-3′, or 5′-CTTC-3′.

### Claim 41 (depends on 39, 40)

The RNA guide of claim 39 or 40, wherein the target sequence is immediately adjacent to the PAM sequence.

### Claim 42 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A nucleic acid encoding an RNA guide of any one of claims 25 to 41.

### Claim 43 (depends on 42)

A vector comprising the nucleic acid of claim 42.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A vector system comprising one or more vectors encoding (i) the RNA guide as defined in any of claims 1 to 41 and (ii) a Cas12i polypeptide, optionally wherein the vector system comprises a first vector encoding the RNA guide and a second vector encoding the Cas12i polypeptide.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A cell comprising the composition of any one of claims 1 to 24, the RNA guide of any one of claims 25 to 41, the nucleic acid of claim 42, the vector of claim 43, or the vector of claim 44.

### Claim 46 (depends on 45)

The cell of claim 45, wherein the cell is a eukaryotic cell, an animal cell, a mammalian cell, a human cell, a primary cell, a cell line, a stem cell, or a T cell.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A kit comprising the composition of any one of claims 1 to 24, the RNA guide of any one of claims 25 to 41, the nucleic acid of claim 42, the vector of claim 43, or the vector system of claim 44.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A method of editing a B2M sequence, the method comprising contacting a B2M sequence with a composition of any one of claims 1 to 24 or an RNA guide of any one of claims 25 to 41.

### Claim 49 (depends on 48)

The method of claim 48, wherein the B2M sequence is in a cell.

### Claim 50 (depends on 48, 49)

The method of claim 48 or 49, wherein the composition or the RNA guide induces a deletion in the B2M sequence.

### Claim 51 (depends on 50)

The method of claim 50, wherein the deletion is adjacent to a 5′-NTTN-3′ sequence, wherein N is any nucleotide.

### Claim 52 (depends on 50, 51)

The method of claim 50 or 51, wherein the deletion is downstream of the 5′-NTTN-3′ sequence.

### Claim 53 (depends on 50, 51, 52)

The method of any one of claims 50 to 52, wherein the deletion is up to about 50 nucleotides in length.

### Claim 54 (depends on 50, 51, 52, 53)

The method of any one of claims 50 to 53, wherein the deletion is up to about 40 nucleotides in length.

### Claim 55 (depends on 50, 51, 52, 53, 54)

The method of any one of claims 50 to 54, wherein the deletion is from about 4 nucleotides to 40 nucleotides in length.

### Claim 56 (depends on 50, 51, 52, 53, 54, 55)

The method of any one of claims 50 to 55, wherein the deletion is from about 4 nucleotides to 25 nucleotides in length.

### Claim 57 (depends on 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 50 to 56, wherein the deletion is from about 10 nucleotides to 25 nucleotides in length.

### Claim 58 (depends on 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 50 to 57, wherein the deletion is from about 10 nucleotides to 15 nucleotides in length.

### Claim 59 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 50 to 58, wherein the deletion starts within about 5 nucleotides to about 15 nucleotides of the 5′-NTTN-3′ sequence.

### Claim 60 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 50 to 59, wherein the deletion starts within about 5 nucleotides to about 10 nucleotides of the 5′-NTTN-3′ sequence.

### Claim 61 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 50 to 60, wherein the deletion starts within about 10 nucleotides to about 15 nucleotides of the 5′-NTTN-3′ sequence.

### Claim 62 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 50 to 61, wherein the deletion starts within about 5 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 63 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 50 to 62, wherein the deletion starts within about 5 nucleotides to about 10 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 64 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 50 to 63, wherein the deletion starts within about 10 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 65 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 50 to 64, wherein the deletion ends within about 20 nucleotides to about 30 nucleotides of the 5′-NTTN-3′ sequence.

### Claim 66 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 50 to 65, wherein the deletion ends within about 20 nucleotides to about 25 nucleotides of the 5′-NTTN-3′ sequence.

### Claim 67 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 50 to 66, wherein the deletion ends within about 25 nucleotides to about 30 nucleotides of the 5′-NTTN-3′ sequence.

### Claim 68 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 50 to 67, wherein the deletion ends within about 20 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 69 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 50 to 68, wherein the deletion ends within about 20 nucleotides to about 25 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 70 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 50 to 69, wherein the deletion ends within about 25 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 71 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 50 to 70, wherein the deletion starts within about 5 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 20 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 72 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 50 to 71, wherein the deletion starts within about 5 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 20 nucleotides to about 25 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 73 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 50 to 72, wherein the deletion starts within about 5 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 25 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 74 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 50 to 73, wherein the deletion starts within about 5 nucleotides to about 10 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 20 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 75 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 50 to 74, wherein the deletion starts within about 5 nucleotides to about 10 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 20 nucleotides to about 25 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 76 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 50 to 75, wherein the deletion starts within about 5 nucleotides to about 10 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 25 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 77 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 50 to 76, wherein the deletion starts within about 10 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 20 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 78 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 50 to 77, wherein the deletion starts within about 10 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 20 nucleotides to about 25 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 79 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 50 to 78, wherein the deletion starts within about 10 nucleotides to about 15 nucleotides downstream of the 5′-NTTN-3′ sequence and ends within about 25 nucleotides to about 30 nucleotides downstream of the 5′-NTTN-3′ sequence.

### Claim 80 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 50 to 79, wherein the 5′-NTTN-3′ sequence is 5′-CTTT-3′, 5′-CTTC-3′, 5′-GTTT-3′, 5′-GTTC-3′, 5′-TTTC-3′, 5′-GTTA-3′, or 5′-GTTG-3′.

### Claim 81 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 50 to 80, wherein the deletion overlaps with a mutation in the B2M sequence.

### Claim 82 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 50 to 81, wherein the deletion overlaps with an insertion in the B2M sequence.

### Claim 83 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method of any one of claims 50 to 82, wherein the deletion removes a repeat expansion of the B2M sequence or a portion thereof.

### Claim 84 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 50 to 83, wherein the deletion disrupts one or both alleles of the B2M sequence.

### Claim 85

The composition, RNA guide, nucleic acid, vector, cell, kit or method of any one of the previous claims, wherein the RNA guide does not consist of the sequence of:
(SEQ ID NO: 778)
AGAAAUCCGUCUUUCAUUGACGGAAUGUCGGAUGGAUGAAACC;
(SEQ ID NO: 779)
AGAAAUCCGUCUUUCAUUGACGGCUAUCUCUUGUACUACACUG;
(SEQ ID NO: 780)
AGAAAUCCGUCUUUCAUUGACGGACACGGCAGGCAUACUCAUC;
or
(SEQ ID NO: 781)
AGAAAUCCGUCUUUCAUUGACGGGUCACAGCCCAAGAUAGUUA.

### Claim 86

The composition, RNA guide, nucleic acid, vector, cell, kit or method of any one of the previous claims, wherein the RNA guide comprises the sequence of any one of SEQ ID NOs: 1222-1230.
